201037-95-8

Basic information

• Product Name: 4,7,10-Trioxa-3-siladodecan-12-ol, 2,2,3,3-tetramethyl-
• CAS NO: 201037-95-8
• Molecular Formula: C12H28O4Si
• Molecular Weight: 264.437
• Mol File: 201037-95-8.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 4,7,10-Trioxa-3-siladodecan-12-ol, 2,2,3,3-tetramethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4,7,10-Trioxa-3-siladodecan-12-ol, 2,2,3,3-tetramethyl-(201037-95-8)
• EPA Substance Registry System: 4,7,10-Trioxa-3-siladodecan-12-ol, 2,2,3,3-tetramethyl-(201037-95-8)

Safety Data

• Hazardous Substances Data: 201037-95-8(Hazardous Substances Data)

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 

Downstream Products

• 199484-66-7 toluene-4-sulfonic acid 2-{2-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-ethoxy}-ethyl ester 
• 1447810-65-2 (E)-8,8-bis(phenylsulfonyl)-12-hydroxy-1,14,17-trioxacyclononadecan-10-en-2-one 
• 1447810-59-4 7,7-bis(phenylsulfonyl)heptanoic acid 2-[2-(3-vinyloxiranylmethoxy)ethoxy]ethyl ester 
• 208827-90-1 O-propargyl triethylene glycol 
• 943601-31-8 C₃₁H₄₆F₃N₉O₇S 
• 943601-30-7 C₃₇H₄₉F₃N₁₀O₁₁S₂ 
• 943601-78-3 tert-butyl (2-(2-(2-(2-nitrophenylsulfonamido)ethoxy)ethoxy)ethyl)carbamate 
• 943601-24-9 (2-[2-azidoethoxy]ethyl)-N-nosylethanamine 
• 943601-23-8 N-(2-[2-{2-hydroxyethoxy}ethoxy]ethyl)-2-nitro-benzenesulfonamide 
• 943601-22-7 C₁₈H₃₂O₇SiSN₂ 
• 109-16-0 triethyleneglycol dimethacrylate 
• 495417-68-0 2-[2-[2-[(tert-butyldimethylsilyl)oxy]ethoxy]ethoxy]ethyl methacrylate 
• 6338-55-2 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol 

Relevant articles and documents

Total synthesis of a biotinylated derivative of phorboxazole A via Sonogashira coupling

The C46 terminus of phorboxazole A has been modified to incorporate a biotin-terminated linker via direct palladium-mediated Sonogashira reaction conditions. Synthetic 45,46-dehydrobromophorboxazole A was joined with a tris-(polyethyleneglycol)vinyl iodid

PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER

There are provided compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers. (I)

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.